Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Lung cancer is uncontrollable rise of abnormal cells that develop in one or both lungs generally in bronchi. They are not get converted into healthy lung tissue. They divide and redivide at rapid rates and develop tumours. In most of cases smoking is prime cause of lung cancer. As the tumour size increases the ability of lungs to provide oxygen in bloodstream is also decreases. Primary lung cancer develop in lungs and secondary lung cancer is initiate at other parts of body. There is different types of cancer treatment varies from type to type are available. Cigarette smoke contains minimum 73 carcinogens that are responsible to develop cancer in lungs.
The Europe lung cancer diagnostic market is observing rapid growth during forecast period of 2021 to 2027. Increase in earlier starting of smoking and increase in number of daily cigarette smoking is achieving attention of peoples for development of lung cancer diagnostic market. The key factors such as rising rate of early detection owing to rise in awareness about lung cancers is propelling growth of Europe lung cancer diagnostic market. Rising adoption of unhealthy lifestyles is also boosting growth of Europe lung cancer diagnostic market. However, lack of healthcare infrastructure is restraining growth of Europe lung cancer diagnostic market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the lung cancer diagnostic market. In addition, complete analysis of changes on lung cancer diagnostic expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on Europe economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The COVID-19 has almost affected every market is healthcare industries positively or negatively. The lung cancer diagnostic market is also experienced somewhat negative impact of COVID-19. As due to lockdown, physicians where treating only emergency cases whereby the other diagnostic procedure where postponed. The lung cancer patients are at higher risk of COVID-19 infections. After the slight relaxation the market is growing at significant rates. The market is get resumed with use of mask and maintaining social distancing as per the government guidelines.
The Europe lung cancer diagnostic market is categorised into cancer type, diagnostic test, end user and country.
Based on cancer type, the Europe lung cancer diagnostic market is segmented into small cell lung cancer and non-small cell lung cancer. In which non-small cell lung cancer is expected as dominating segment of market in 2020. The non-small cell lung cancer is major types of lung cancer that affects both smokers and non-smokers. It is group of lung cancers that behave similarly such as squamous cell carcinoma and adenocarcinoma. The symptoms of non-small cell lung cancer includes uncontrolled cough, shortness of breath, weight loss and coughing up blood. The non-small cell lung cancer have more survival rates than the small cell lung cancers.
Based on diagnostic test, the Europe lung cancer diagnostic test is bifurcated into biomarkers test, imaging test, biopsy and other test. The biomarkers test is sub-categorised into the CA test, HER2 Test, ALK Test, Angiogenesis Inhibitors, KRAS mutation test. Likewise, Imaging test is also sub-segmented into computed tomography scan, positron emission tomography scan and chest x-ray. The biopsy sub-segmented into needle biopsy, bronchoscopy biopsy and open biopsy. In which biopsy segment is also contributing to the growth of Europe lung cancer diagnostic market. The biopsy is a medical test which is commonly performed by the surgeons, interventional radiologist or an interventional cardiologist. It is process which comprised of the extraction of sample cells or tissues for examination for determination of presence and extent of disease.
Based on end users, the Europe lung cancer diagnostic market is categorised into the hospital associated labs, independent diagnostic laboratories and cancer research institutes. In which cancer research institutes is also contributing to the growth of Europe lung cancer diagnostic market. The rising research and development activities in healthcare industries is propelling growth of Europe lung cancer diagnostic market. The rising number of early smokers is also boosting growth of Europe lung cancer diagnostic market.
The Europe lung cancer diagnostic market is studied for key countries such as United Kingdom, Germany, France, Italy and Spain. In which United Kingdom is anticipated to dominate the market in 2020. The lung cancer is biggest killer in Europe with compared to other cancer types. Smoking is leading cause of lung cancer in Europe region. The growing number of lung cancer patient’s is propelling growth of Europe lung cancer diagnosis market. The economic development of region is also refuelling the growth of Europe lung cancer diagnostic market. Additionally, new product launches and collaboration of key players driving the growth of Europe lung cancer diagnostic market.
The major key players operating in the lung cancer diagnostic market are Illumina Inc., Abbott, Thermo Fisher Scientific Inc., Qiagen, Quest Diagnostics Incorporated, Neogenomics, Nanostring Technologies Inc, Myriad Genetics Inc, Roche Holding Ag, Danaher, Agilent Technologies, Astrazeneca, Sanofi, Janssen Pharmaceuticals, Biomérieux Sa, Ge Healthcare, Hologic, Koninklijke Philips N.V, Biotheranostics and Exact Sciences among others.
March 2021 Agilent Technologies Inc., entered into a definitive agreement to acquire Resolution Bioscience Inc., a leader in the development and commercialization of next-generation sequencing (NGS)-based precision oncology solutions.
March 2020, Thermo Fisher Scientific entered into a partnership with Janssen Biotech, a part of Johnson & Johnson to develop lung cancer companion diagnostic.
July 2020, AnchorDx, a leading biotechnology company developing novel NGS-based early cancer detection and disease monitoring tests, entered into a multi-year collaboration with the Lung Cancer Initiative at Johnson & Johnson to conduct a lung cancer study.
June 2019, Roche, launched in-vitro lung cancer diagnostic test VENTANA ROS1 (SP384) to target ROS1 positive lung cancer.
The report analyses the lung cancer diagnostic market based on cancer type, diagnostic test, end user and country. Various types of lung cancers covered in the lung cancer diagnostic market are small cell lung cancer and non-small cell lung cancers. By diagnostic test, the market is segmented into the biomarkers test, imaging test, biopsy and others. Based on end users, the market is segmented into the hospital associated labs, independent diagnostic laboratories and cancer research institutes. The report also imparts the impact of COVID-19 on the lung cancer diagnostic market and it founds that the COVID-19 has almost affected every market is healthcare industries positively or negatively. The lung cancer diagnostic market is also experienced somewhat negative impact of COVID-19. As due to lockdown, physicians where treating only emergency cases whereby the other diagnostic procedure where postponed. The lung cancer patients are at higher risk of COVID-19 infections. After the slight relaxation the market is growing at significant rates. The market is get resumed with use of mask and maintaining social distancing as per the government guidelines. The report also analyses the major key players operating in the market.
Why to buy this report
